Skip to main content

Table 2 Clinical events of the patients in the propensity score matched cohort

From: The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Outcome (HR or SHR)

GLP1RA (n = 602)

DPP4i (n = 1479)

HR/SHR (95% CI) of GLP1RA

P

n (%)

Incidence (95% CI)a

n (%)

Incidence (95% CI)a

Cardiovascular outcome

 Composite CV outcomeb (HR)

78 (13.0)

6.0 (4.7–7.4)

204 (13.79)

6.9 (6.0–7.9)

0.88 (0.68–1.13)

0.308

 Cardiovascular death (HR)

34 (5.6)

2.5 (1.7–3.4)

81 (5.5)

2.6 (2.0–3.1)

0.97 (0.66–1.44)

0.894

 Myocardial infarction (SHR)

41 (6.8)

3.1 (2.2–4.1)

99 (6.7)

3.3 (2.7–4.0)

0.96 (0.67–1.38)

0.843

 Ischemic stroke (SHR)

20 (3.3)

1.5 (0.9–2.18)

52 (3.5)

1.7 (1.2–2.15)

0.91 (0.54–1.52)

0.708

Renal outcome (SHR)

 eGFR decline > 50%

113 (32.2)

17.1 (14.0–20.3)

319 (35.9)

22.4 (20.0–24.9)

0.74 (0.60–0.91)

0.005

 Progression to ESKD with dialysis

82 (23.4)

11.4 (8.9–13.9)

244 (27.5)

15.9 (13.9–17.9)

0.72 (0.56–0.93)

0.010

 Composite renal outcomec

134 (38.2)

23.2 (19.3–27.1)

393 (44.2)

34.3 (30.9–37.7)

0.75 (0.61–0.93)

0.009

Secondary outcome

 All-cause death (HR)

111 (18.4)

8.3 (6.8–9.9)

371 (25.1)

12.0 (10.8–13.2)

0.71 (0.57–0.88)

0.002

 Heart failure admission (SHR)

77 (12.8)

6.2 (4.8–7.5)

222 (15.1)

8.0 (6.9–9.0)

0.80 (0.61–1.05)

0.102

 Admission due to any cause (SHR)

343 (57.0)

42.5 (38.0–47.0)

906 (61.3)

54.7 (51.2–58.3)

0.81 (0.71–0.91)

0.001

 Composite MALE outcomed (SHR)

42 (7.0)

3.3 (2.3–4.3)

132 (8.9)

4.5 (3.7–5.2)

0.74 (0.52–1.05)

0.094

 Hypoglycemia (SHR)

45 (7.5)

3.5 (2.5–4.5)

117 (7.9)

4.0 (3.3–4.7)

0.89 (0.64–1.23)

0.479

 DKA/HHS (SHR)

83 (13.8)

6.8 (5.3–8.2)

170 (11.5)

6.0 (5.1–6.9)

1.15 (0.88–1.51)

0.315

  1. Data are presented as frequency (percentage)
  2. GLP1RA glucagon-like peptide-1 receptor agonist; DPP4i dipeptidyl peptidase 4 inhibitor; HR hazard ratio; SHR subdistribution hazard ratio; CI confidence interval; eGFR estimated glomerular filtration rate; ESKD end-stage kidney disease; MALE major adverse limb event; DKA diabetic ketoacidosis; HHS hyperglycemic hyperosmolar state
  3. aNumber of events per 100 person-years
  4. bComposite of cardiovascular death, myocardial infarction or ischemic stroke
  5. cComposite of eGFR decline > 50%, progression to ESKD with dialysis or cardiovascular death
  6. dComposite of newly-diagnosed peripheral arterial disease, claudication, clinical limb ischemia, limb revascularization or amputation
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840